(HealthDay News) – An implantable device can accurately predict seizures in patients whose epilepsy is resistant to drugs, according to a study published online May 2 in The Lancet Neurology.
Mark J. Cook, MD, from St. Vincent’s Hospital in Melbourne, Australia, and colleagues surgically implanted a seizure advisory device into 15 adults with drug-resistant focal seizures. Patients initially entered a data collection phase to construct an algorithm of seizure likelihood. If the sensitivity of high-likelihood warnings was ≥65%, patients entered an advisory phase for four months.
The researchers found that there were eleven device-related adverse events. Eleven patients met performance sensitivity criteria and entered the advisory phase, with high seizure likelihood sensitivities of 65–100%. In eight of these patients, the performance of the warning device was better than expected by chance.
“This study showed that intracranial electroencephalographic monitoring is feasible in ambulatory patients with drug-resistant epilepsy,” Cook and colleagues conclude.
The study was funded by NeuroVista; several authors are employees of the company.